VISITING SPEAKERS PROGRAM IN ONCOLOGY

2019-2020

VISITING SPEAKERS PROGRAM IN ONCOLOGY SEPTEMBER 2019 – JULY 2020

The McGill Continuing Professional Development Office has made available, webcasts of the

presentations.

Speaker Date(s) Institution Title(s) of Presentation(s) September – December 2019

Dr. Michael Wang October 23 University of Texas

MD Anderson Cancer

Center

Houston, TX

USA

Relapsed/Refractory Mantle Cell

Lymphoma.

Dr. Steven P. Treon November 6, 7 Dana-Farber Cancer

Institute

Harvard Medical

School

Boston, MA

USA

Recent advances and treatments for

Waldenstrom’s Macroglobulinemia.

January – July 2020 Dr. Geoffrey Liu January 22, 23 Princess Margaret

Cancer Centre

University of Toronto

Toronto, ON

CANADA

Canadian rare molecular sub-type lung

cancer registry. Its promises, realizations

and potential applications.

Dr. Caron A. Jacobson February 12, 13 Dana-Farber Cancer

Institute

Harvard Medical

School

Boston, MA

USA

CAR T and DLBCL: From clinical trials

to real world clinic.

Dr. Christian Kollmannsberger May 13, 14, 19,

20

BC Cancer Agency

Vancouver Cancer

Centre

Vancouver, BC

CANADA

VIRTUAL PRESENTATION

Exploring options in metastatic RCC-

Indications and challenges in the use of

immunotherapy.

Dr. Ghassan Abou-Alfa July 8, 9, 10, 15 Memorial Sloan

Kettering Cancer

Center

Weill Cornell Medical

College

Cornell University

New York, NY

USA

VIRTUAL PRESENTATION

A decade of systemic treatments of

hepatocellular carcinoma: From a myth

to a central role.

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by theCommittee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program ofthe Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American MedicalAssociation, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit canbe found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For moreinformation, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp Request for certificate: vspo@mcgill.ca / 514 398-2496

This program has received an educational grant from:AbbVie, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Merck, Novartis, Pfizer,Roche, Seattle Genetics, Servier, Takeda, Teva Canada Innovation

LEARNING OBJECTIVES

• Discuss the evolution of treatment in relapsed/refractory mantle cell lymphoma (MCL)with focus on new therapies

• Review optimal patient management strategies and best practice• Understand the multidisciplinary roles in patient assessment and treatment

“Relapsed/Refractory Mantle Cell Lymphoma”

WEDNESDAY Oct 23, 2019

MUHC- GLEN8:30 - 9:30Room D02.1312

Hôpital Charles LeMoyne 12:00 – 13:00Room HN-106(lecture by videoconference from CHUS Sherbrooke)

CHUS Sherbrooke (not a VSPO-affiliated lecture)

12:00 – 13:00Room X5-7512

WEDNESDAY Oct 23, 2019

CHUM 17:00 - 18:00 Room D.S4.5030Live on the Web! www.vpsolution.tv/vspoProblems/Questions: 514-813-4510

Gerald Bronfman Department of Oncology | McGill University

Michael Wang, M.D.Professor, Department of Lymphoma & Myeloma Founding and Current Director, Mantle Cell Lymphoma Program of Excellence University of Texas, MD Anderson Cancer Center, Houston, TX

Refreshments will be served.To organize a videconference:

vspo@mcgill.ca

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by theCommittee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program ofthe Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American MedicalAssociation, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit canbe found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For moreinformation, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp Request for certificate: vspo@mcgill.ca / 514 398-2496

This program has received an educational grant from:AbbVie, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Merck, Novartis, Pfizer,Roche, Seattle Genetics, Servier, Takeda, Teva Canada Innovation

LEARNING OBJECTIVES

• Discuss the latest clinical data in Waldenstrom’s Macroglobulinemia• Identify the best treatment options for their patients with Waldenstrom’s Macroglobulinemia;• Apply the latest data to clinical cases

“Recent Advances and Treatments for Waldenstrom’s Macroglobulinemia”

WEDNESDAY Nov 6, 2019

MUHC- GLEN

8:30 - 9:30

Room D02.1312Live on the Web! www.vpsolution.tv/vspo Problems/Questions: 514-813-4510

Hôpital Maisonneuve-Rosemont12:00 – 13:00Room SS-080

CHUM 17:00 - 18:00 Room D.S4.5030

THURSDAY Nov 7, 2019

Jewish General Hospital 12:30 - 1:30 Room E-711

Gerald Bronfman Department of Oncology | McGill University

STEVEN P. TREON, MD, PHD, FRCP, FACP Professor of Medicine at the Dana Farber Cancer Institute

Director of the Bing Center for Waldenstrom’s Macroglobulinemia

Harvard Medical School, Boston, MA

Refreshments will be served.To organize a videconference:

vspo@mcgill.ca

This program has received an educational grant from:AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Servier, Takeda, Teva Canada Innovation

LEARNING OBJECTIVES

• To discuss the value of Real World Evidence when considering rare tumor types in NSCLC• To explore the importance of creating a Canadian study to collect historic and prospective data

on incidence, treatment and outcomes.• To consider the logistics of creating a Canadian comprehensive registry on rare NSCLC tumors• To evaluate the eventual utility of such a resource for the various stakeholders.

“Canadian rare molecular sub-type lung cancer registry. Its promises, realizations and potential applications.”

WEDNESDAY Jan 22, 2020

CHUS Sherbrooke (not a VSPO-affiliated lecture)

12:00 – 13:00 Room X1-S149

Hôpital Charles LeMoyne 12:00 – 13:00Room HN-106(lecture by videoconference from CHUS Sherbrooke)

CHUM 17:00 - 18:00 Room D.S4.5030www.vpsolution.tv/vspo Problems/Questions: 514-813-4510

THURSDAY Jan 23, 2020

MUHC- GLEN8:00 - 9:00Room D02-4250

Jewish General Hospital 12:00 - 13:00 Room H-433 (Pavilion H - 4th Floor)

Gerald Bronfman Department of Oncology | McGill University

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by theCommittee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program ofthe Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American MedicalAssociation, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit canbe found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For moreinformation, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp Request for certificate: vspo@mcgill.ca / 514 398-2496

GEOFFREY LIU, MD, MSc, F.R.C.P.C. Senior Scientist, Princess Margaret Cancer CentreAlan B. Brown Chair in Molecular GenomicsAssociate Professor, Department of Medicine and Medical Biophysics University of Toronto, Ontario

Refreshments will be served.To organize a videconference:

vspo@mcgill.ca

This program has received an educational grant from:Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Eisai, Gilead a Kite Company, Janssen, Merck, Pfizer, Roche, Servier, Taiho Pharma, Takeda, TevaCanada Innovation

LEARNING OBJECTIVES

• Review of the unmet need in DLBCL and the place for CAR T therapy• Highlight CAR constructs• Present data from key landmark CAR T studies as well as CAR T pivotal trials in DLBCL• Discuss emerging real world evidence from the use of CAR T therapies in clinical practice

“CAR T and DLBCL: From clinical trials to real world clinic.”

WEDNESDAY Feb 12, 2020

MUHC- GLEN8:30 - 9:30Room D02.1312

Hôpital Maisonneuve-Rosemont-HMR 12:00 – 13:00 Room 0-80

CHUM 17:00 - 18:00 Room D.S4.5030Live on the Web! www.vpsolution.tv/vspo Problems/Questions: 514-813-4510

THURSDAY Feb 13, 2020

Hôpital Sacré-Coeur 12:00 - 13:00 Room G- 4115

Gerald Bronfman Department of Oncology | McGill University

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by theCommittee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program ofthe Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American MedicalAssociation, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit canbe found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For moreinformation, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp Request for certificate: vspo@mcgill.ca / 514 398-2496

Caron A. Jacobson, MDMedical Director, Immune Effector Cell Therapy ProgramDana-Farber Cancer InstituteAssistant Professor of Medicine, Harvard Medical School Boston, USA

Refreshments will be served.To organize a videconference:

vspo@mcgill.ca

This program has received an educational grant from:Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Eisai, Gilead a Kite Company, Janssen, Merck, Pfizer, Roche, Servier, Taiho Pharma, Takeda, TevaCanada Innovation, Mylan Canada

LEARNING OBJECTIVES

• Identify the appropriate patients for immunotherapy-based combination treatment, as recommended by the KCRNC consensus statement, for patients with advanced RCC

• Contextualize the available immunotherapy-based combination treatments based on duration of response and potential side effects

• Exchange and identify best practice in managing adverse events with immunotherapy-based combination treatment

“Exploring Options in Metastatic RCC – Indications and Challenges in the Use of Immunotherapy”

WEDNESDAY May 13, 202012:00 - 13:00Live on the Web! www.vpsolution.tv/vspoProblems/Questions: 514-813-4510

TUESDAY May 19, 20208:00 – 9:00 Live on the Web! www.vpsolution.tv/vspo Problems/Questions: 514-813-4510

THURSDAY May 14, 202020:00 - 21:00 Live on the Web! www.vpsolution.tv/vspoProblems/Questions: 514-813-4510

WEDNESDAY, May 20th, 202020:00 - 21:00 Live on the Web! www.vpsolution.tv/vspoProblems/Questions: 514-813-4510

Gerald Bronfman Department of Oncology | McGill University

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by theCommittee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program ofthe Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American MedicalAssociation, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit canbe found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For moreinformation, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp Request for certificate: vspo@mcgill.ca / 514 398-2496

/ƘNJƛǎǘƛŀƴ YƻƭƭƳŀƴƴǎōŜNJƎŜNJ/ƭƛƴƛŎŀƭ tNJƻŦŜǎǎƻNJ ŀǘ ǘƘŜ ¦ ƻŦ ./ aŜŘƛŎŀƭ ƻƴŎƻƭƻƎƛǎǘ ŀǘ ǘƘŜ ./ /ŀƴŎŜNJ !ƎŜƴŎȅ ό.//!ύ±ŀƴŎƻdzǾŜNJ /ŀƴŎŜNJ /ŜƴǘNJŜ, BC

VIRTUAL PRESENTATION https://www.vpsolution.tv/vspo/en

Hôpital Sacre Coeur de Montréal12h00-13h00

FRI Jul 10, 2020

CHUM17:00 - 18:00

WED Jul 15, 2020

Hôpital Charles Lemoyne12:00 - 13:00

CHUS Sherbrooke12:00 - 13:00

WED July 8, 2020

VISITING SPEAKERS PROGRAM IN ONCOLOGYPROGRAMME DE PROFESSEURS INVITÉS EN ONCOLOGIE

Ghassan Abou-Alfa, MD

Gerald Bronfman Department of Oncology | McGill UniversityV PO

"A Decade of Systemic Treatments of HepatocellularCarcinoma: From a Myth to a Central Role"

Medical Oncologist, Memorial Sloan Kettering Cancer Center Professor, Weill Cornell College at Cornell UniversityNew York, USA

• Discuss the optimal treatment of HCC in the context of the pandemic

• Discuss the latest HCC treatment algorithms, and the algorithms of the future: how to choosepatients

• Understand the importance of managing the side effects of TKI for the success of therapy

LEARNING OBJECTIVES

MUHC-GLEN8:00 - 9:00

JGH12:30 - 13:30

THUR July 9, 2020

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/international-cme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, Request for certificate: vspo@mcgill.ca

This program has received an educational grant from:Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Eisai, Gilead a Kite Company, Janssen, Merck, Pfizer, Roche, Servier, Taiho Pharma, Takeda, TevaCanada Innovation, Mylan Canada

VIRTUAL PRESENTATION

LIVE ON THE WEB!

https://vspo.ca/participate/Problems/Questions: 514-813-4510